Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

A new PET scan tracks brain tumors by their appetite for tryptophan

NCT ID NCT07735819

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is testing whether a special PET/CT scan that uses a radioactive form of tryptophan can provide better information about gliomas (a type of brain tumor) than standard MRI. The study has three parts: seeing if the scan can better define the tumor for radiation planning, distinguishing tumor regrowth from radiation damage, and measuring whether a drug (minocycline) can block a metabolic pathway in low-grade tumors. Adults with newly diagnosed or treated gliomas are eligible.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
a radioactive tracer called [18F]FETrp used in PET/CT scans, and in one arm the drug minocycline is also given
What this could lead to
If successful, this imaging method could help doctors more accurately target radiation therapy and distinguish tumor growth from treatment-related changes, potentially improving outcomes for people with brain tumors.
What could go wrong
This is a relatively small, early-phase trial, so the imaging technique may not prove superior to MRI. The drug minocycline may cause side effects and may not effectively block the pathway as hoped.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 61 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

FOR ARMS 1-3 Inclusion Criteria: * Age =18 years. * Patient is able to lie in the PET/CT scanner for at least 60 minutes while undergoing scanning. * Patient is willing and able to review, understand, and provide written consent for the study procedures and indicates that they are aware of the investigational nature of this study. Exclusion Criteria: * Patients who are pregnant or lactating are excluded. Premenopausal women (defined per institutional guidelines) must have a negative pregnancy test (urine or serum) within 7 days of the PET scan. * Severe increased intracranial pressure, status epilepticus, or other severe or progressing clinical symptoms requiring urgent intervention in the opinion of the treating * Karnofsky performance score \<60, as determined by one of the clinician co- investigators. ADDITIONAL CRITERIA FOR ARM 1: Inclusion Criteria: * Histopathology/cytopathological diagnosis of a glioblastoma without a history of radiation. * The tumor is deemed amenable for radiation treatment (pre-radiation planning MRI can be done before or after the PET scan). ADDITIONAL CRITERIA FOR ARM 2: Inclusion Criteria: * Previous histopathology/cytopathological diagnosis of glioblastoma. * History of glioma radiation. * Presence of a new or progressing enhancing brain lesion on follow-up clinical MRI suspicious for post-radiation glioma progression or late radiation-induced MRI changes (i.e., radiation injury), at least 7 mm in bidirectional diameter. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks of the planned PET scan. ADDITIONAL CRITERIA FOR ARM 3 Inclusion Criteria: * MRI diagnosis of a brain tumor, previously verified to be a low-grade (WHO grade 2, IDH (isocitrate dehydrogenase) mutant glioma, based on histopathology from biopsy or resection. * The detected mass on the most recent clinical MRI is at least 7 mm in bidirectional diameter (i.e., twice the PET scanner resolution). * The tumor does not require urgent (within 1 month) resection, steroid treatment, or radiation. * The most recent MRI, used for comparison with the PET/CT, is performed within 4 weeks. * Patient agrees to have a baseline and follow-up PET/CT scan (approximately 1 month later) and interval oral treatment with 200mg/day minocycline. * Due to planned minocycline treatment, patients will need to have adequate renal function Exclusion Criteria: * Active connective tissue disorders, such as lupus or scleroderma. * History of allergic reaction to minocycline or any tetracyclines. * Ongoing treatment with warfarin with INR \> 1.5. * History of colitis during antibiotics treatment.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Glioblastoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.